Skip to main content

Lytenava FDA Approval Status

FDA Approved: No
Brand name: Lytenava
Generic name: bevacizumab-vikg
Dosage form: Intravitreal Injection
Company: Outlook Therapeutics

Lytenava (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab in development for the treatment of wet AMD and other retinal diseases.

Development timeline for Lytenava

Mar 31, 2022Outlook Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.